Pipeline
Overview
HomePipelineOverview
| Program | Indication | Early discovery |
Late discovery |
Pre-clinical | Phase I | Phase II / III | ||
|---|---|---|---|---|---|---|---|---|
| Angiogenesis | ABL001 (Anti-VEGF/DLL4 BsAb) |
Solid cancer |
|
|||||
|
Dual VEGF/DLL4 Inhibition Overcomes VEGF Therapy Resistance Dual Blockade of VEGF & DLL4 overcomes VEGF resistance 
ABL001 is BETTER than Avastin 
|
||||||||
| Immuno-Oncology | Grabody™ T Platform (Multiple Pipelines) ABL10X |
Cancer |
|
|||||
| Grabody™ T/I Platform ABL50X |
Cancer |
|
||||||
| I/O mAb ABL40X |
Cancer |
|
||||||
| Antibody-Drug Conjugate (ADC) |
ABL20X | Cancer |
|
|||||
|
Brief Summary of ADC Pipeline Site-specific ADC (LegoChem Collaboration) 
ABL202: ADC for Solid Cancer and Leukemia 
ABL203: ADC for Solid Cancer 
|
||||||||
| Neurology | Grabody™ B (BBB Shuttle) (ɑ-Synuclein / BBB: ABL301) |
Parkinson’s Disease |
|
|||||